Unité de Fabrication des Médicaments S.A (BVMT:UMED)

Market Cap	268.80M
Revenue (ttm)	153.79M
Net Income (ttm)	22.22M
Shares Out	32.00M
EPS (ttm)	0.69
PE Ratio	12.10
Forward PE	11.35
Dividend	0.57 (6.79%)
Ex-Dividend Date	Aug 26, 2025

Volume	11,802
Average Volume	31,594
Open	8.50
Previous Close	8.50
Day's Range	8.30 - 8.50
52-Week Range	6.83 - 9.60
Beta	0.04
RSI	57.71
Earnings Date	Dec 5, 2025

About BVMT:UMED

Unité de Fabrication des Médicaments S.A. develops, manufactures, markets, and sells generic medicines under the UNIMED brand in Tunisia, Africa, Asia, and Europe. The company offers Opthalmic, ENT, and inhalation solutions, infusion solutions, injectable fluids and penicillin, and cephalosporin powders, as well as vaigtaine products in approximately 40 presentations for various therapeutic classes. It manufactures medicines for third party laboratories principals. Unité de Fabrication des Médicaments S.A. was founded in 1989 and is based in So...

• Industry: Pharmaceutical Preparations
• Founded: 1989
• Employees: 572
• Stock Exchange: Tunis Stock Exchange
• Ticker Symbol: UMED

Financial Performance

In 2024, BVMT:UMED's revenue was 147.68 million, an increase of 8.58% compared to the previous year's 136.00 million. Earnings were 19.37 million, an increase of 249.30%.